When it comes to investing in medical stocks, many investors focus on the big names. However, there's one stock that's flying under the radar but has immense potential: OncoSil Medical (ASX: OSL). Recently, the company has garnered attention due to significant investments and involvement from prominent figures like Peter Hall and Gilman Wong, both of whom have a track record of turning companies into billion-dollar enterprises. Here’s why OncoSil Medical should be on your investment radar.

The Power Players: Peter Hall and Gilman Wong

Peter Hall is a London-based Australian financier, media proprietor, and philanthropist. He founded Hunter Hall Investment Management in 1993 and served as Chief Investment Officer and Executive Chairman for 23 years. Hall is also a well-known philanthropist, having donated millions to animal conservation causes and earning a Member of the Order of Australia for his charitable efforts.

Recently, Hall made a significant investment in OncoSil Medical, acquiring 38,000,000 securities, representing a 2.535% stake in the company. Hall's involvement didn’t stop there; he will be appointed as a Non-Executive director of OncoSil Medical by the end of August 2024. His expertise and strategic vision are expected to drive OncoSil Medical’s growth to heights.

Gilman Wong, another heavyweight in the medical industry, also recently invested in OncoSil Medical. Wong, who acquired 30,000,000 securities (2.002% stake), was the CEO of Sirtex Medical, a company that sold for billions. His backing of OncoSil indicates strong confidence in the company’s long term potential.  

OncoSil Medical: Shaking Up Cancer Treatment

Imagine a world where a diagnosis of pancreatic cancer isn't a death sentence. OncoSil Medical Limited (ASX: OSL) is striving to make that a reality with its groundbreaking OncoSil device. This isn’t just another medical gadget; it’s a game-changer in the treatment of locally advanced, unresectable pancreatic cancer, a disease that is notorious for its grim prognosis and limited options.

Pancreatic cancer is the silent killer, the 12th most common cancer in men and 11th in women globally, with around 500,000 new cases each year. It is often detected too late, and its survival rates are disheartening. But OncoSil Medical could be the company changing this narrative. Their device delivers targeted beta-radiation directly into pancreatic tumours using Phosphorous-32 (32P) under endoscopic ultrasound guidance. 

OncoSil’s innovations have not gone unnoticed. The OncoSil device has earned breakthrough device designations in the European Union, the United Kingdom, and the United States. It’s also CE Marked, meaning it meets rigorous safety and performance standards and can be marketed across the EU and UK. Currently, the device is approved for sale in over 30 countries, including Türkiye and Israel, with initial treatments already making a difference in Spain, Italy, Türkiye, Greece and Israel.

Why OncoSil Medical Stands Out

1. Innovative Technology: OncoSil Medical’s brachytherapy device represents a significant advancement in the treatment of locally advanced unresectable pancreatic cancer. By delivering beta-radiation directly to the pancreatic cancer tumour, it minimises damage to surrounding healthy tissues, offering a more effective, less invasive and targeted treatment option.
2. Regulatory Approvals: The device’s breakthrough designations and CE marking in major markets demonstrate its potential and pave the way for broader adoption and commercialisation.
3. Promising Clinical Results: Ongoing clinical trials are essential for validating the effectiveness of the OncoSil™ device. The positive results so far indicate that the company is on the right track.
4. Strong Market Potential: With pancreatic cancer cases expected to rise, there is a significant market opportunity for effective treatments like the OncoSil™ device.

The Impact of Hall and Wong’s Involvement

The involvement of Peter Hall and Gilman Wong in OncoSil Medical could be perceived as a price sensitive announcement by itself. Both have a proven track record of identifying and nurturing high-potential companies. Hall's appointment as Non-Executive Director brings a wealth of strategic insights and experience that can help guide OncoSi Medical to become the next top medical device company. 

Gilman Wong’s investment is equally significant. As the former CEO of Sirtex Medical, Wong played a crucial role in transforming Sirtex into a billion-dollar company. His backing of OncoSil Medical may suggest that he sees similar potential in this company.

What’s next for OncoSil Medical?

With strong financial backing and strategic guidance from industry veterans like Hall and Wong, OncoSil Medical is set for substantial growth. The company is moving towards commercialising its OncoSil™ device and expanding its market presence. Investors can expect to see continued advancements in clinical trials and increased adoption of the device in international markets.

Final Thoughts

OncoSil Medical is the best medical stock that not nearly enough people are talking about. The recent investments and involvement from Peter Hall and Gilman Wong are strong indicators of the company’s potential and with its innovative pancreatic cancer treatment device device, regulatory approvals, and promising clinical results, OncoSil Medical is well-positioned for significant growth. If you’re looking for a high-potential investment in the healthcare sector, OncoSil Medical should be at the top of your list.